Literature DB >> 15017643

Expression of epidermal growth factor receptor in gastric carcinomas.

Takuo Takehana1, Kazuyoshi Kunitomo, Shioto Suzuki, Koji Kono, Hideki Fujii, Yoshiro Matsumoto, Akishi Ooi.   

Abstract

BACKGROUND & AIMS: Epidermal growth factor receptor belongs to the family of type I receptor tyrosine kinases. Overexpression of epidermal growth factor receptor has been observed in a variety of cancers with or without amplification of the gene. Novel chemotherapies targeting receptor tyrosine kinases might be effective for the treatment of cancers in which overexpression of this protein is a feature. The aim of this study was to assess the potential efficacy of epidermal growth factor receptor-targeted therapy in gastric cancer. This was achieved by determining the frequency of increased epidermal growth factor receptor expression in gastric cancers and investigating the relationship between protein overexpression and gene amplification.
METHODS: Immunohistochemical evaluation of 413 gastric cancers was carried out by using a monoclonal antibody to the epidermal growth factor receptor. The intensity of reactivity was scored by using a 4-tier system (negative, 1+, 2+, and 3+). All positive staining (>1+) tumors overexpressing the protein were then analyzed for gene amplification by fluorescence in situ hybridization by using a gene-specific probe.
RESULTS: High levels of overexpression (2+ or 3+ staining) were found in 9 of 413 (2.2%) patients, whereas low levels of overexpression (1+) were found in 34 (8.2%) of the study cohort. Fluorescence in situ hybridization analysis showed that more than 10 copies of the gene were recognized in all 5 cancers with 3+ staining and in 2 of the 4 tumors with 2+ staining.
CONCLUSIONS: Although a high level of overexpression of epidermal growth factor receptor is uncommon in gastric carcinomas, it almost exclusively occurs by gene amplification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15017643     DOI: 10.1016/s1542-3565(03)00219-2

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

1.  Antibody-based targeted therapy for gastric cancer.

Authors:  Florian Lordick; Christian Peschel; Jörg Rüdiger Siewert
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 2.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

3.  Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.

Authors:  Akishi Ooi; Takeru Oyama; Ritsuko Nakamura; Ryosuke Tajiri; Hiroko Ikeda; Sachio Fushida; Hiroyuki Nakamura; Yoh Dobashi
Journal:  Mod Pathol       Date:  2015-03-06       Impact factor: 7.842

4.  Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma.

Authors:  Gang Lin; Xiao-Jiang Sun; Qian-Bo Han; Zhun Wang; Ya-Ping Xu; Jia-Lei Gu; Wei Wu; G U Zhang; Jin-Lin Hu; Wen-Yong Sun; Wei-Min Mao
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

5.  A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Authors:  J A Chan; L S Blaszkowsky; P C Enzinger; D P Ryan; T A Abrams; A X Zhu; J S Temel; D Schrag; P Bhargava; J A Meyerhardt; B M Wolpin; P Fidias; H Zheng; S Florio; E Regan; C S Fuchs
Journal:  Ann Oncol       Date:  2011-01-07       Impact factor: 32.976

6.  Epidermal growth factor receptor status in anaplastic thyroid carcinoma.

Authors:  Dae Ho Lee; Geon Kook Lee; Sun-Young Kong; Myoung Chul Kook; Sun Kyung Yang; So Yeon Park; Seong Hoe Park; Bhumsuk Keam; Do Joon Park; Bo Youn Cho; Seok Won Kim; Ki-Wook Chung; Eun Sook Lee; Sun Wook Kim
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

7.  EGFR and HER2 expression in advanced biliary tract cancer.

Authors:  Jan Harder; Oliver Waiz; Florian Otto; Michael Geissler; Manfred Olschewski; Brigitte Weinhold; Hubert E Blum; Annette Schmitt-Graeff; Oliver G Opitz
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

8.  Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection.

Authors:  Long Sun; Huang-Yang Ye; Ying-Hong Zhang; Yong-Song Guan; Hua Wu
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

9.  Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.

Authors:  Shin-Ae Lee; Seok-Reyol Choi; Jin-Seok Jang; Jong-Hun Lee; Myung-Hwan Roh; Sang Ock Kim; Min-Chan Kim; Su-Jin Kim; Jin-Sook Jeong
Journal:  Dig Dis Sci       Date:  2009-09-12       Impact factor: 3.199

10.  Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

Authors:  C Pinto; F Di Fabio; C Barone; S Siena; A Falcone; S Cascinu; F L Rojas Llimpe; G Stella; G Schinzari; S Artale; V Mutri; S Giaquinta; L Giannetta; A Bardelli; A A Martoni
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.